Brokerages Set Ascendis Pharma A/S (NASDAQ:ASND) PT at $204.64

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) has been assigned a consensus rating of "Moderate Buy" from the fourteen brokerages that are covering the firm, Marketbeat.com reports. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company. The average 1 year target price among brokerages that have issued a report on the stock in the last year is $204.64.

A number of brokerages have recently issued reports on ASND. Cantor Fitzgerald boosted their target price on shares of Ascendis Pharma A/S from $170.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, February 25th. JPMorgan Chase & Co. lifted their price target on shares of Ascendis Pharma A/S from $168.00 to $200.00 and gave the company an "overweight" rating in a research note on Tuesday, March 18th. Evercore ISI lifted their target price on Ascendis Pharma A/S from $220.00 to $260.00 and gave the company an "outperform" rating in a research report on Tuesday, February 18th. UBS Group began coverage on Ascendis Pharma A/S in a research note on Tuesday, January 7th. They set a "buy" rating and a $196.00 price target on the stock. Finally, The Goldman Sachs Group increased their target price on shares of Ascendis Pharma A/S from $200.00 to $225.00 and gave the stock a "buy" rating in a report on Thursday, February 13th.

Institutional Trading of Ascendis Pharma A/S

Several large investors have recently bought and sold shares of ASND. Virtus ETF Advisers LLC lifted its stake in shares of Ascendis Pharma A/S by 3.9% during the fourth quarter. Virtus ETF Advisers LLC now owns 2,676 shares of the biotechnology company's stock worth $368,000 after buying an additional 100 shares during the period. Legato Capital Management LLC lifted its position in Ascendis Pharma A/S by 7.5% during the 4th quarter. Legato Capital Management LLC now owns 1,921 shares of the biotechnology company's stock worth $264,000 after acquiring an additional 134 shares during the period. Jones Financial Companies Lllp lifted its position in Ascendis Pharma A/S by 394.0% during the 4th quarter. Jones Financial Companies Lllp now owns 247 shares of the biotechnology company's stock worth $34,000 after acquiring an additional 197 shares during the period. Point72 Asia Singapore Pte. Ltd. purchased a new stake in Ascendis Pharma A/S during the 4th quarter valued at about $28,000. Finally, Wilmington Savings Fund Society FSB acquired a new position in shares of Ascendis Pharma A/S in the third quarter valued at about $30,000.

Remove Ads

Ascendis Pharma A/S Stock Performance

NASDAQ ASND traded down $3.02 on Tuesday, hitting $158.02. 154,295 shares of the stock were exchanged, compared to its average volume of 479,779. Ascendis Pharma A/S has a 52-week low of $111.09 and a 52-week high of $169.37. The firm has a market capitalization of $9.59 billion, a P/E ratio of -22.26 and a beta of 0.62. The stock has a fifty day moving average price of $142.64 and a two-hundred day moving average price of $136.45.

Ascendis Pharma A/S (NASDAQ:ASND - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The biotechnology company reported ($0.68) EPS for the quarter, beating the consensus estimate of ($1.32) by $0.64. Sell-side analysts expect that Ascendis Pharma A/S will post -4.34 earnings per share for the current fiscal year.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.